On the other hand, expression of MYC and BCL2 (double expressor) without translocation occurs in about 30% of DLBCL, the risk of CNS relapse appears to be increased in patients with activated B cell subtype and intermediate or high-risk CNS-IPI [26]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.